131 related articles for article (PubMed ID: 37666437)
1. FTIR Microspectroscopy as a new probe to study human uterine lesions: Characterization of tumor cell lines from uterine smooth muscle cells and evaluation of EPA and DHA in vitro treatments.
Belloni A; Notarstefano V; Greco S; Pellegrino P; Giorgini E; Ciarmela P
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166873. PubMed ID: 37666437
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 fatty acids modulate the lipid profile, membrane architecture, and gene expression of leiomyoma cells.
Islam MS; Castellucci C; Fiorini R; Greco S; Gagliardi R; Zannotti A; Giannubilo SR; Ciavattini A; Frega NG; Pacetti D; Ciarmela P
J Cell Physiol; 2018 Sep; 233(9):7143-7156. PubMed ID: 29574773
[TBL] [Abstract][Full Text] [Related]
3. Uterine leiomyoma as useful model to unveil morphometric and macromolecular collagen state and impairment in fibrotic diseases: An ex-vivo human study.
Belloni A; Furlani M; Greco S; Notarstefano V; Pro C; Randazzo B; Pellegrino P; Zannotti A; Carpini GD; Ciavattini A; Di Lillo F; Giorgini E; Giuliani A; Cinti S; Ciarmela P
Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166494. PubMed ID: 35850176
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound features of highly vascularized uterine myomas (uterine smooth muscle tumors) and correlation with histopathology.
Russo C; Camilli S; Martire FG; Di Giovanni A; Lazzeri L; Malzoni M; Zupi E; Exacoustos C
Ultrasound Obstet Gynecol; 2022 Aug; 60(2):269-276. PubMed ID: 35018681
[TBL] [Abstract][Full Text] [Related]
5. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
Shanes ED; Friedman LA; Mills AM
Am J Surg Pathol; 2019 Jun; 43(6):792-801. PubMed ID: 31009388
[TBL] [Abstract][Full Text] [Related]
7. Pathologic considerations of uterine smooth muscle tumors.
Prayson RA; Hart WR
Obstet Gynecol Clin North Am; 1995 Dec; 22(4):637-57. PubMed ID: 8786875
[TBL] [Abstract][Full Text] [Related]
8. PTEN, tau-AP-3, thymidylate synthase immunohistochemistry scoring expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignancy potential and uterine leiomyosarcomas.
Huang LC; Ye JC; Hsieh CH; Chen LM; Lin TY; Hung YC; Chang WC
Eur J Gynaecol Oncol; 2011; 32(5):496-9. PubMed ID: 22053660
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
10. Targeting Hedgehog Pathway and DNA Methyltransferases in Uterine Leiomyosarcoma Cells.
Garcia N; Al-Hendy A; Baracat EC; Carvalho KC; Yang Q
Cells; 2020 Dec; 10(1):. PubMed ID: 33396427
[TBL] [Abstract][Full Text] [Related]
11. Biomarker resolution of uterine smooth muscle tumor necrosis as benign vs malignant.
Yang EJ; Mutter GL
Mod Pathol; 2015 Jun; 28(6):830-5. PubMed ID: 25698060
[TBL] [Abstract][Full Text] [Related]
12. Pathology, cytogenetics and molecular biology of uterine leiomyomas and other smooth muscle lesions.
Quade BJ
Curr Opin Obstet Gynecol; 1995 Feb; 7(1):35-42. PubMed ID: 7742513
[TBL] [Abstract][Full Text] [Related]
13. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
[TBL] [Abstract][Full Text] [Related]
14. Fascin expression in uterine smooth muscle tumors.
Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
[TBL] [Abstract][Full Text] [Related]
15. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
16. Expression and intracellular localization of ACA and TRA-1-81 in smooth muscle cell tumors.
Sukhikh GT; Becker-Kojić Z; Kogan EA; Demura TA; Faizullina NM; Nizyaeva NV; Schott A; Ureña-Peralta JJ; Askol'skaya SI; Popov YV
Bull Exp Biol Med; 2013 Aug; 155(4):530-5. PubMed ID: 24143384
[TBL] [Abstract][Full Text] [Related]
17. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of promyelocytic leukemia zinc finger and histone 1.5 in uterine leiomyosarcoma and leiomyoma.
Momeni M; Kalir T; Farag S; Kinoshita Y; Roman TY; Chuang L; Fishman DA; Burstein DE
Reprod Sci; 2014 Sep; 21(9):1171-6. PubMed ID: 24784718
[TBL] [Abstract][Full Text] [Related]
19. Uterine smooth-muscle tumor of uncertain malignant potential metastasizing to the humerus as a high-grade leiomyosarcoma.
Shapiro A; Ferenczy A; Turcotte R; Bruchim I; Gotlieb WH
Gynecol Oncol; 2004 Sep; 94(3):818-20. PubMed ID: 15350379
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
